Clinical trial

International Genetic Obesity Registry

Recruiting now · Not applicable · 1 countries · Registry ID NCT07296900

Recruiting nowNot applicableObservational

What this study is about

Genetic obesity results from changes in specific genes that affect appetite regulation, metabolism, and fat storage. Its severity and associated health issues vary depending on the genetic cause. In some cases, hormonal imbalances, developmental delays, or other complications may also occur. Identifying the genetic cause is essential for personalized treatment and understanding potential symptoms. As genetic obesity is rare, specialists often encounter few patients with diverse genetic backgrounds and clinical features. Therefore, collecting global data is crucial to improve our understanding of the condition's progression, complications, and treatment responses for each genetic subtype. To support this, the International Genetic Obesity Registry (iGO Registry) has been established to gather detailed patient information on genetic obesity. This registry will help advance research and improve clinical care for affected individuals. It will collect data from routine outpatient visits, focusing on relevant diagnostic and treatment information on an international level.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

AgeNot listed to Not listed

SexAll

Healthy volunteersNot accepted

ConditionGenetic Obesity

Full registry criteria

Inclusion Criteria: * Patients with * genetically confirmed genetic obesity (ACMG classification 3-5, associated with obesity) and/or * early onset severe obesity (BMI ≥ 120% 95th percentile or ≥ 35 kg/m2 before 5 years of age) if genetic testing was performed * Capable of understanding the aims of the protocol and to provide informed consent (for children and chronically incapacitated individuals, consent is given by their legal guardians) Exclusion Criteria: * Not capable of understanding the aims of the protocol and to provide informed consent

Treatments and study arms

The registry does not list a named intervention.

Primary outcomes

Change of somatic comorbidities under standard treatmentevery 5 years for 50 years

Number of participants with abnormal physical examination findings under standard treatment. Physical examinations include: Body weight \[kg\], body height \[cm\], blood pressure \[mmHg\], heart rate \[bpm\].

Change of somatic comorbidities under standard treatmentevery 5 years for 50 years

Number of participants with abnormal laboratory test results. Laboratory measurements include. HbA1c \[%\], blood lipids \[mmol/l\], insulin \[mU/l\], glucose \[mg/dl\]

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Ulm University Clinic🇩🇪 Ulm, Germany

Open map

Julia von Schnurbein, PD Dr.Contact

Email · Call 0049 731 500 57401